医药生物行业周报：AI医疗+创新药仍是核心主线，Q2行业边际改善趋势或更明显

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Viewpoints - The report emphasizes that AI healthcare and innovative drugs remain the core investment themes, with a more apparent trend of marginal improvement in the industry expected in Q2 2025 [4][11] - The report highlights significant recent developments, including successful clinical trials of a new brain-spinal interface and Huawei's establishment of a healthcare division focused on AI-assisted diagnostics [4][11] - The report anticipates continued speculation around AI healthcare themes and a focus on companies with strong Q1 performance as the industry prepares for annual report releases [4][11] Summary by Sections Market Performance - The pharmaceutical and biotechnology sector recorded a weekly return of +1.06%, underperforming the CSI 300 by -0.32%, ranking 19th among 31 primary sub-industry indices [4][11] - The medical services sub-sector had the highest weekly increase of 2.63%, while the medical devices sub-sector had the lowest increase of 0.17% [4][11] Industry Dynamics - Notable advancements include the first successful clinical trials of a "three-in-one" brain-spinal interface and Huawei's formation of a healthcare division to develop AI diagnostic solutions [4][11] - The report suggests that if macro policies progress smoothly, the overall pharmaceutical industry may see marginal improvements in Q2 2025, following a -1% year-on-year revenue decline in Q2 2024 [4][11] Investment Directions - AI-enabled drug development is highlighted, with recommendations to focus on companies like Crystal Technology Holdings and Via Biotechnology [4][11] - AI's role in reducing costs and improving medical service efficiency is emphasized, with suggested companies including Kingmed Diagnostics and Aier Eye Hospital [4][11] - The report also points to AI's potential in gene multi-omics development, recommending companies such as BGI Genomics and DaAn Gene [4][11] Company Performance - Companies expected to exceed Q1 performance include those benefiting from the flu season, such as InnoCare Pharma and Shengxiang Biology [12] - The report notes that the medical services sub-sector has shown strong performance, with a monthly increase of 9.98% [4][11]